靶向IGHV4-34 B细胞受体的CAR T细胞特异性清除肿瘤性及自身免疫性B细胞
研究开发了靶向携带IGHV4-34的B细胞受体(BcR)的CAR T细胞(CART4-34),在体外对IGHV4-34+恶性B细胞显示特异性细胞毒性和细胞因子分泌,在HBL1细胞系异种移植小鼠模型中表现出与CART19相当的扩增和抗肿瘤活性,并可靶向SLE的IGHV4-34+ B细胞及清除自身抗体而不影响健康B细胞或总IgG滴度。
要点
- CART4-34特异性靶向IGHV4-34+恶性B细胞并减少抗原阴性逃逸风险
- 缩短CAR铰链区可优化CAR与BcR结合并改善免疫突触形态和体内活性
- CART4-34可体外靶向SLE的IGHV4-34+ B细胞并清除自身抗体
核心结论
- CART4-34可特异性靶向淋巴恶性肿瘤和SLE中的致病性B细胞,为精准细胞治疗提供潜力。
研究设计与样本
- 开发靶向携带IGHV4-34的BcR的CAR T细胞(CART4-34),并进行体外细胞毒性和细胞因子分泌检测、HBL1细胞系来源异种移植小鼠模型体内实验以及SLE患者样本体外实验。
主要发现
- CART4-34对IGHV4-34+恶性B细胞显示特异性细胞毒性和细胞因子分泌。
- CART19治疗后复发时CD19下调,而CART4-34治疗后复发时IGHV4-34+ BcR水平保持完整,提示抗原阴性逃逸风险降低。
- 在IGHV4-34+ HBL1细胞系来源异种移植小鼠模型中,CART4-34显示强劲扩增和与CART19相当的抗肿瘤活性。
- 使用更短CAR铰链域优化CAR:BcR结合可改善免疫突触形态和体内活性。
- CART4-34可靶向人IGHV4-34+ SLE B细胞并体外清除IGHV4-34+自身抗体,而不靶向健康B细胞或影响总IgG滴度。
临床怎么用
- CART4-34有望作为淋巴恶性肿瘤和SLE的精准细胞治疗选择,减少对正常B细胞的损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current US Food and Drug Administration-approved chimeric antigen receptor (CAR) T cell therapies for B cell leukemias and lymphomas target CD19, which is widely expressed across the B cell lineage, often leading to on-target, off-tumor B cell depletion, prolonged immune suppression, and antigen-negative escape in a subset of patients. In contrast, B cell receptor (BcR) signaling is essential for the survival of most mature B cell neoplasms, and BcRs carrying the immunoglobulin heavy variable gene IGHV4-34 are highly enriched in B cell malignancies compared with normal B cells. Further, self-reactive IGHV4-34+ serum autoantibodies are enriched in aggressive systemic lupus erythematosus (SLE) and other autoimmune diseases. Here, we developed CAR T cells targeting the BcR carrying IGHV4-34 (CART4-34). We found that CART4-34 showed specific cytotoxicity and cytokine secretion toward IGHV4-34+ malignant B cells. In addition, although CD19 was down-regulated upon relapse after treatment with CART19, IGHV4-34+ BcR levels remained intact upon relapse after treatment with CART4-34, suggesting reduced risk of antigen-negative escape. In IGHV4-34+ HBL1 cell line-derived xenograft mouse models, CART4-34 showed robust expansion and antitumor activity comparable to those of CART19. Optimized CAR:BcR binding using shorter CAR hinge domains improved immune synapse morphology and in vivo activity. In addition, we showed that CART4-34 could target human IGHV4-34+ SLE B cells and deplete IGHV4-34+ autoantibodies ex vivo, without targeting healthy B cells or affecting total IgG titers. In conclusion, we developed a CAR T cell product that specifically targets pathogenic B cells in lymphoid malignancies and SLE, offering potential for precision cell therapy for these indications.
引用
- Cohen IJ, Bochi-Layec AC, Lemoine J, et al. Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. Sci Transl Med. 2026. PMID: 41637528. doi:10.1126/scitranslmed.adr9382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。